Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US.

Document Type

Article

Publication Date

4-2025

Publication Title

Future Oncol

Abstract

AIMS: Androgen deprivation therapy (ADT) is standard for advanced prostate cancer. Relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, is the only oral ADT, with limited real-world data on therapy persistence and adherence. This retrospective study evaluates persistence and adherence of relugolix, degarelix, and GnRH agonists (leuprolide, goserelin, triptorelin, histrelin) using data from the IBM MarketScan Research Database (Jan 2017 - Dec 2022).

METHODS: The IBM MarketScan Research Database (1 January 2017 - 31 December 2022) was used for enrollment history and claims. ADT adherence was measured by the proportion of days covered (PDC) at 3, 6, and 12 months, calculated as days on ADT divided by period duration. Kaplan-Meier analysis assessed treatment persistence by measuring time to treatment discontinuation.

RESULTS: Relugolix had higher adherence (PDC ≥ 80%) at 12 months (60.8%) compared to degarelix (13.0%) and GnRH agonists (46.3%). Median time to discontinuation was also longer for relugolix (13.5 months) than degarelix (3.1 months) and GnRH agonists (8.8 months). Persistence and adherence rates were higher in metastatic prostate cancer.

CONCLUSIONS: Findings support relugolix use as an oral treatment due to its favorable persistence and long-term adherence profiles.

Volume

21

Issue

10

First Page

1219

Last Page

1230

DOI

10.1080/14796694.2025.2480050

ISSN

1744-8301

PubMed ID

40189880

Link to Full Text

Share

COinS